Prelude Capital Management, LLC Arcus Biosciences, Inc. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $450,501 - $712,777	-17,221 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $292,757 - $557,271	17,221 New	17,221 $447,000
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $129,544 - $192,502	-7,558 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$13.97 - $36.56 $11,650 - $30,491	-834 Reduced 9.94%	7,558 $187,000
Q1 2020 May 15, 2020	BUY	$8.78 - $19.28 $73,681 - $161,797	8,392 New	8,392 $116,000
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $14,155 - $22,375	-2,198 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $16,023 - $29,409	2,198 New	2,198 $17,000
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.95 $3,264 - $4,485	-300 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$12.24 - $17.05 $3,672 - $5,115	300 New	300 $4,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.